Clinical trials: Daptomycin
Antibiotics, Subcutaneous Injection
Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC)
Background: Multidrug-resistant bacteria are a major public health problem worldwide, notably due to excess mortality and an increase in the length of hospital stay.
- Conditions
- Antibiotics, Subcutaneous Injection, Daptomycin
- Trial name
- DAPTOSC (NCT04434300)
- Testing
- Daptomycin
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Bone Infection, Joint Infection
Population Pharmacokinetic Analysis of Daptomycin in Patients With Osteoarticular Infections
Daptomycin is validated as a treatment of bone and joint infections by the Infectious Disease Society of America. However, most of studies did not investigate daptomycin pharmacokinetics in this indication while it is known that…
- Trial name
- NCT03134521
- Volunteers
- 189 people
- Sponsor
- Hospices Civils de Lyon
Bone and Joint Infection, Patient Treated by Daptomycin
Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections
Daptomycin is a cyclic lipopeptide that has been proposed as an alternative therapeutic option in patients with prosthetic joint infection caused by Staphylococcus or Enterococcus species in the latest Infectious Diseases Society…
- Trial name
- NCT03209921
- Volunteers
- 23 people
- Sponsor
- Hospices Civils de Lyon
Soft Tissue Infections
Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections
multicenter, randomized (1:1), semi-single blind study comparing the safety and efficacy of HDSD daptomycin (10 mg/kg q24h for 4 days) with that of comparator (vancomycin +/- SSP for 7-14 days) in patients with cSSSI due to…
- Trial name
- NCT00426933
- Testing
- Daptomycin, Vancomycin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Wound Infections
Cubicin(R) for Complicated Post-surgical Wound Infections
The purpose of the study is to describe the clinical efficacy of CUBICIN therapy in patients with superficial and deep post-surgical Gram-positive wound infections
- Trial name
- PSW (NCT00651131)
- Testing
- daptomycin
- Volunteers
- 69 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Gram-Positive Bacterial Infections
Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Finding Study
Daptomycin kinetics in CRRT Trial with medicinal product
- Trial name
- NCT01212432
- Testing
- Daptomycin
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- University of Zurich
Bacteremia
Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)
There is an increased failure rate for the treatment of Staphylococcus Aureus Bacteremia (SAB) with traditional doses of vancomycin, the standard of care for patients with MRSA bacteremia over the last 40 years.
- Trial name
- NCT01287832
- Testing
- Vancomycin, Daptomycin
- Volunteers
- 11 people
- Sponsor
- St. John Health System, Michigan
Staphylococcal Skin Infections
Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections
This study will evaluate the safety and efficacy of daptomycin against complicated skin and skin-structure infections in adults
- Trial name
- NCT00463801
- Testing
- Daptomycin
- Where
- 2 sites in Italy
- Volunteers
- 52 people
- Sponsor
- Novartis
Bacteremia Due to Staphylococcus Aureus
Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia
The aim of this study is to compare the efficacy of daptomycin treatment versus vancomycin treatment in the treatment of methicillin resistant staphylococcus aureus (MRSA) bloodstream infections (BSI) due to isolates with high…
- Trial name
- NCT01975662
- Testing
- Daptomycin, Vancomycin
- Where
- Singapore
- Volunteers
- 14 people
- Sponsor
- Singapore General Hospital
Dactinomycin Adverse Reaction, Bone and Joint Infection
Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections
the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection
- Trial name
- PKTOXDAP (NCT04933344)
- Testing
- patients having had BJI or PJI treated with daptomycin
- Where
- France
- Volunteers
- 1,130 people
- Sponsor
- Hospices Civils de Lyon
Peritoneal Infection
Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Peritoneal Infection
Peritoneal infection is still a frequent complication in peritoneal dialysis patients . In France, It contributes to the technique failure, responsible for about 20% of cases of transfer in hemodialysis.
- Trial name
- DAPTODP (NCT02000414)
- Testing
- intraperitoneal daptomycin
- Where
- France
- Volunteers
- 8 people
- Sponsor
- University Hospital, Caen
Pneumococcal Meningitis
Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis
Pneumococcal meningitis is an infection of the membrane that covers the brain. It is a serious infection which is currently treated with a combination of corticosteroids (dexamethasone) and 3rd generation cephalosporins.
- Trial name
- AddaMAP (NCT03480191)
- Testing
- Daptomycin
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Bacteremia
Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
The intent of this study is to describe the safety and efficacy of daptomycin versus standard of care (SOC) in pediatric participants aged 1-17 years with bacteremia caused by Staphylococcus aureus (S. aureus).
- Trial name
- NCT01728376
- Testing
- Daptomycin, Comparator
- Volunteers
- 82 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cellulitis
The Effects of Daptomycin and Cytokines Production in Comparison With Vancomycin
Primary: To determine the influence of daptomycin on inflammatory cytokine (IL-1, TNF and IL-6) for the treatment of complicated cellulitis/erysipela compared with alternative treatment (vancomycin or oxacillin).
- Trial name
- NCT01626560
- Testing
- Daptomycin, Vancomycin
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital Universitario Evangelico de Curitiba
Bloodstream Infection
Catheter Related - Gram Positive Bloodstream Infections
Primary Objective: -Evaluate the clinical efficacy and safety of Daptomycin given for treatment of catheter-related bloodstream infections (CRBSI) due to gram positive bacteremia in the context of standard of care antimicrobial…
- Trial name
- NCT00467272
- Testing
- Daptomycin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Bacteremia, Soft Tissue Infections
Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)
The purpose of this study is to assess the safety, efficacy and pharmacokinetic (PK) parameters of daptomycin for injection in Japanese pediatric participants aged 1 to 17 years with complicated skin and soft tissue infection…
- Conditions
- Bacteremia, Soft Tissue Infections, Skin Diseases, Infectious
- Trial name
- NCT03643952
- Testing
- Daptomycin for Injection
- Where
- 16 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Hematogenous Osteomyelitis
Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
The purpose of the study is to determine whether daptomycin is effective and safe in the treatment of pediatric participants with AHO when compared to vancomycin (or equivalent) or nafcillin (or β-lactam equivalent).
- Trial name
- NCT01922011
- Testing
- Daptomycin, Vancomycin (or equivalent), Nafcillin (or equivalent)
- Volunteers
- 149 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Drug Interactions, Pharmacokinetics
Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin
The purpose of this study is to understand how an antibiotic, rifampin, may change the blood levels of another antibiotic, daptomycin, in the body.
- Trial name
- NCT02097953
- Testing
- Daptomycin, Rifampin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Utah
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
This is a multicenter, randomized, evaluator-blinded, comparator-controlled study. Participants were to be randomized (1:1) to daptomycin or comparator, stratified by degree of renal impairment (creatinine clearance [CLcr] 30 …
- Conditions
- Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
- Trial name
- RENSE (NCT01104662)
- Testing
- Vancomycin, Daptomycin, Semi-Synthetic Penicillin
- Where
- 10 sites in United States
- Volunteers
- 92 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Antimicrobial Prophylaxis
A Pilot Study of Daptomycin for Antimicrobial Prophylaxis
The goals of the study are to evaluate the feasibility of using daptomycin as a prophylactic antimicrobial agent in patients undergoing cardiac surgery, to determine the rates of surgical site infection, and to evaluate the…
- Trial name
- NCT00572260
- Testing
- daptomycin 6 mg/kg IV
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Duke University